Clover nears pivotal trial of GSK-adjuvanted COVID-19 vaccine

Clover Biopharmaceuticals is set to start a phase 2/3 clinical trial of a COVID-19 vaccine featuring an adjuvant from GlaxoSmithKline. The Chinese vaccine developer committed to starting the study later this month after reviewing data on 150 participants in a phase 1 trial.